A. Wissner

发表

Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.

D. Boschelli, D. Berger, M. Dutia, 2003, Bioorganic & medicinal chemistry letters.

Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies

N. Brooijmans, A. Wissner, T. Mansour, 2009 .

Kinase domain mutations in cancer: implications for small molecule drug design strategies.

Allan Wissner, Natasja Brooijmans, N. Brooijmans, 2009, Journal of medicinal chemistry.

4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.

D. Boschelli, R. Nilakantan, D. Berger, 2000, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.

D. Powell, A. Wissner, M. B. Floyd, 2000, Bioorganic & medicinal chemistry letters.

Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.

A. Wissner, M. B. Floyd, K. Arndt, 2009, Bioorganic & medicinal chemistry letters.

Determination of the loading values for high levels of drugs and sugars conjugated to proteins by matrix‐assisted ultraviolet laser desorption/ionization mass spectrometry

M. Karas, A. Wissner, F. Hillenkamp, 1993 .

Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.

M. Dutia, A. Wissner, J. Bloom, 1992, Journal of medicinal chemistry.

The Efficient Synthesis of Two Prostaglandin Intermediates

A. Wissner, P. Hamann, 1989 .

Hypotensive and vasodilatory activity of (+/-) 1-o-octadecyl-2-acetyl glyceryl-3-phosphorylcholine in the normotensive rat.

A. Wissner, P. Cervoni, F. Lai, 1983, Life sciences.

4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.

D. Boschelli, R. Nilakantan, D. Berger, 2000, Journal of medicinal chemistry.

Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses

A. Wissner, C. Kohler, E. Tarrant, 1993, Inflammation.

The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).

A. Wissner, M. B. Floyd, K. Arndt, 2010, European journal of medicinal chemistry.

Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.

D. Boschelli, D. Berger, M. Dutia, 2003, Bioorganic & medicinal chemistry letters.

Role of K(V)LQT1 in cyclic adenosine monophosphate-mediated Cl(-) secretion in human airway epithelia.

A. Wissner, R. Schreiber, K. Kunzelmann, 2000, American journal of respiratory cell and molecular biology.

Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.

D. Boschelli, A. Wissner, Xiaoke Yang, 2009, Bioorganic & medicinal chemistry letters.

Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.

A. Wissner, C. Kohler, B. Goldstein, 1984, Journal of medicinal chemistry.

Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.

S. Kerwar, A. Wissner, C. Kohler, 1992, Journal of medicinal chemistry.

PROSPECTS FOR A PROSTAGLANDIN BRONCHODILATOR

J. Skotnicki, A. Wissner, M. J. Weiss, 1980 .

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

R. Nilakantan, A. Wissner, C. Discafani, 2001, Journal of medicinal chemistry.

Inhibition of amiloride-sensitive epithelial Na(+) absorption by extracellular nucleotides in human normal and cystic fibrosis airways.

A. Wissner, K. Kunzelmann, T. Gonska, 2000, American journal of respiratory cell and molecular biology.

Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes

A. Wissner, K. Kunzelmann, R. Greger, 2000, British journal of pharmacology.

Defective cholinergic Cl(-) secretion and detection of K(+) secretion in rectal biopsies from cystic fibrosis patients.

A. Wissner, K. Kunzelmann, R. Greger, 2000, American journal of physiology. Gastrointestinal and liver physiology.

Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group.

A. Wissner, C. Kohler, B. Goldstein, 1985, Journal of medicinal chemistry.

Prostaglandins and congeners. 25. Inhibition of gastric acid secretion. Replacement of the carboxylate moiety of a prostaglandin with a hydroxymethylketo functional group.

A. Wissner, D. Wilson, J. Birnbaum, 1980, Journal of medicinal chemistry.

Reaction of tert-butyldimethylsilyl esters with oxalyl chloride-dimethylformamide: preparation of carboxylic acid chlorides under neutral conditions

A. Wissner, C. Grudzinskas, 1978 .

Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.

Ramaswamy Nilakantan, Frank Loganzo, Fei Ye, 2004, Bioorganic & medicinal chemistry letters.

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

R. Nilakantan, F. Loganzo, A. Wissner, 2005, Journal of medicinal chemistry.

Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

F. Loganzo, A. Wissner, M. B. Floyd, 2007, Bioorganic & medicinal chemistry.

R. Nilakantan, A. Wissner, C. Discafani, 2001, Journal of medicinal chemistry.

2-Heterosubstituted silylated ketone acetals: reagents for the preparation of .alpha.-functionalized methylketones from carboxylic acid chlorides

A. Wissner, 1979 .

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Ramaswamy Nilakantan, Fei Ye, Allan Wissner, 2003 .

Tris - trimethylsilyloxyethylene: The conversion of carboxylic acid chlorides to hydroxymethylketones

A. Wissner, 1978 .

HMO Version 1.1: A Hückel molecular orbital program for the Macintosh

Allan Wissner, A. Wissner, 1990 .

Synthesis of tricarbonyliron complexes of functional 1,2-disubstituted cyclobutadienes

A. Wissner, R. Rimerman, B. W. Roberts, 1975 .

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Patricia L. Harris, Allan Wissner, Thomas J Lynch, 2005, Proceedings of the National Academy of Sciences of the United States of America.

15-DEOXY-16-HYDROXYPROSTAGLANDINS SYNTHESIS AND BRONCHODILATOR ACTIVITY

A. Wissner, M. B. Floyd, M. J. Weiss, 1979 .

Asymmetric synthesis of cis- and trans-γ-lactones useful in HIV-1 protease inhibitor synthesis

A. Wissner, G. C. Hsu, M. Trova, 1994 .

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Ramaswamy Nilakantan, Allan Wissner, William A. Hallett, 2004, Cancer Research.

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).

D. Kitchen, Z. Husain, R. Nilakantan, 1999, Biochemical pharmacology.

Combinatorial chemoprevention of intestinal neoplasia

Bert Vogelstein, Kenneth W. Kinzler, Allan Wissner, 2000, Nature Medicine.

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

Ramaswamy Nilakantan, Allan Wissner, R. Nilakantan, 2005, Journal of medicinal chemistry.

Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis

S. Kerwar, A. Wissner, C. Kohler, 1992, Antimicrobial Agents and Chemotherapy.

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

A. Wissner, T. Mansour, 2008, Archiv der Pharmazie.

Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors.

D. Berger, M. Dutia, D. Powell, 2002, Bioorganic & medicinal chemistry letters.

8-Anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src kinase inhibitors.

D. Berger, M. Dutia, D. Powell, 2002, Bioorganic & medicinal chemistry letters.

Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.

S. Kerwar, A. Wissner, C. Kohler, 1993, Journal of Medicinal Chemistry.

Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

Allan Wissner, Nicole Caspers, R. Kurumbail, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of a series of HIV-1 protease inhibitors

M. Wick, R. Babine, S. Kerwar, 1993 .

Prostaglandins and congeners. 11. Synthesis of dl-13-hydroxyprostanoic acids.

A. Wissner, 1977, The Journal of organic chemistry.

MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines.

D. Powell, A. Wissner, C. Kohler, 2001, Bioorganic & medicinal chemistry letters.

Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.

A. Wissner, C. Kohler, B. Goldstein, 1986, Journal of medicinal chemistry.

Tris[trimethylsilyloxy]ethene: A Convenient Preparation of 2,3-Dihydroxyalkanoic Acids From Aldehydes

A. Wissner, 1979 .

Novel ortho effects detected in the fast atom bombardment mass spectra of substituted bisaryl phosphate antagonists of platelet-activating factor

A. Wissner, M. Siegel, R. Tsao, 1993 .

Tricarbonyliron complexes of functional 1,2-disubstituted cyclobutadienes

A. Wissner, R. Rimerman, B. W. Roberts, 1969 .

PROSTAGLANDINS AND CONGENERS. XII. THE SYNTHESIS OF DL-ERYTHRO AND DL-THREO-15,16-DIHYDROXYPROSTAGLANDINS

A. Wissner, M. J. Weiss, W. Hallett, 1978 .

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.

R. Nilakantan, A. Wissner, S. Rabindran, 2002, Bioorganic & medicinal chemistry letters.

Cystic fibrosis and CFTR

A. Wissner, R. Schreiber, K. Kunzelmann, 2001, Pflügers Archiv.

4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors.

D. Powell, Biqi Wu, A. Wissner, 2002, Bioorganic & Medicinal Chemistry Letters.

4‐Anilino‐3‐cyanobenzo[g]quinolines as Kinase Inhibitors.

N. Zhang, D. Powell, Biqi Wu, 2002 .

Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.

D. Boschelli, M. Dutia, D. Powell, 2001, Journal of medicinal chemistry.

Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines.

D. Boschelli, D. Powell, A. Wissner, 2000, Bioorganic & medicinal chemistry letters.

Tris(trimethylsilyloxy)ethylene

A. Wissner, 2001 .

Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.

D. Joseph-McCarthy, A. Wissner, J. Ellingboe, 2008, Journal of medicinal chemistry.

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

A. Wissner, T. Mansour, 2008, Archiv der Pharmazie.